Livzon Pharma to Acquire Roughly 0.13% Stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan

Stock News
11/11

Livzon Pharma (01513) has announced that on November 11, 2026, the company entered into a share transfer agreement with Zhonghuiyuan regarding Xinbeijiang Pharmaceutical, agreeing to acquire approximately 0.13% of Xinbeijiang Pharmaceutical's shares held by Zhonghuiyuan for a cash consideration of approximately RMB 3.8525 million, corresponding to approximately RMB 303,600 of Xinbeijiang Pharmaceutical's registered capital.

Upon completion of the acquisition, the company's direct interest in Xinbeijiang Pharmaceutical will increase from approximately 90.64% to approximately 90.77%.

Zhonghuiyuan serves as an employee shareholding platform for Xinbeijiang Pharmaceutical. In order to further optimize Xinbeijiang Pharmaceutical's equity structure, strengthen the company's control over its core active pharmaceutical ingredient subsidiary, and improve operational decision-making efficiency, the company intends to acquire a portion of the Xinbeijiang Pharmaceutical shares held by Zhonghuiyuan.

This transaction is a normal business arrangement for the company to optimize subsidiary governance and deepen its industrial layout. It aligns with the company's overall strategic development plan and serves the company's long-term development interests as well as the overall interests of all shareholders.

The transaction will not result in any significant changes to the company's current or future financial condition and operating results, nor will it have any adverse impact on the company's daily operations.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10